1. Academic Validation
  2. Novel cyclic biphalin analogue with improved antinociceptive properties

Novel cyclic biphalin analogue with improved antinociceptive properties

  • ACS Med Chem Lett. 2014 Jul 14;5(9):1032-6. doi: 10.1021/ml500241n.
Adriano Mollica 1 Alfonso Carotenuto 2 Ettore Novellino 2 Antonio Limatola 2 Roberto Costante 1 Francesco Pinnen 1 Azzurra Stefanucci 3 Stefano Pieretti 4 Anna Borsodi 5 Reza Samavati 5 Ferenc Zador 5 Sándor Benyhe 5 Peg Davis 6 Frank Porreca 6 Victor J Hruby 6
Affiliations

Affiliations

  • 1 Dipartimento di Farmacia, Università di Chieti-Pescara "G. d'Annunzio" , Via dei Vestini, 31, 66100 Chieti, Italy.
  • 2 Dipartimento di Farmacia, Università di Napoli "Federico II" , Via D. Montesano, 49, 80131 Naples, Italy.
  • 3 Dipartimento di Chimica, Sapienza, Università di Roma , P.le A. Moro, 5, 00187 Rome, Italy.
  • 4 Department of Therapeutic Research and Medicine Evaluation, Istituto Superiore di Sanità , V.le Regina Elena 299, 00161 Rome, Italy.
  • 5 Institute of Biochemistry, Biological Research Centre, Hungarian Academy of Sciences , 6726 Szeged, Hungary.
  • 6 Department of Pharmacology and Department of Chemistry and Biochemistry, University of Arizona , Tucson, Arizona 85721, United States.
Abstract

Two novel opioid analogues have been designed by substituting the native d-Ala residues in position 2,2' of biphalin with two residues of d-penicillamine or l-penicillamine and by forming a disulfide bond between the thiol groups. The so-obtained compound 9 containing d-penicillamines showed excellent μ/δ mixed receptor affinities (K i (δ) = 5.2 nM; K i (μ) = 1.9 nM), together with an efficacious capacity to trigger the second messenger and a very good in vivo antinociceptive activity, whereas product 10 was scarcely active. An explanation of the two different pharmacological behaviors of products 9 and 10 was found by studying their conformational properties.

Keywords

Analgesics; biphalin; cyclic analogues; dimeric opioid peptides.

Figures